Because recombinant thioredoxin has been shown to have neuroprotective effects both in vitro (Bobba et al., 2014; Das et al., 1997; Lee et al., 2003; Zhang et al., 2018, 2012) and in vivo (Hattori et al., 2004; Tian et al., 2014; Wang et al., 2015; Zhang et al., 2009), some authors have proposed it as a prospective option for the treatment of ischemia, where it has been evaluated and all its benefits have been observed (Hattori et al., 2004; Jiao et al., 2020; Tian et al., 2014; Wang et al., 2015; Zhou et al., 2013). This evidence concerns the gene TXN and ischemia.